Front-Line Therapies for Elderly Patients With Transplant-Ineligible Multiple Myeloma and High-Risk Cytogenetics in the Era of Novel Agents

Leukemia - United Kingdom
doi 10.1038/s41375-018-0098-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Melphalan and Prednisone Versus Melphalan, Prednisone and Thalidomide for Elderly and/or Transplant Ineligible Patients With Multiple Myeloma: A Meta-Analysis

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Chromosome 1 Abnormalities in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Therapies

Haematologica
Hematology
2014English

Value of Novel Agents and Intensive Therapy for Patients With Multiple Myeloma

Bone Marrow Transplantation
TransplantationHematology
2013English

Treatment of Multiple Myeloma in Akita: Features and Outcomes in the Era of Novel Agents

Journal of clinical and experimental hematopathology : JCEH
Medicine
2014English

Chemotherapeutic Agents Increase the Risk for Pulmonary Function Test Abnormalities in Patients With Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study From the Japanese Society of Myeloma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

First-Line Therapy With Either Bortezomib-Melphalan-Prednisone or Lenalidomide-Dexamethasone Followed by Lenalidomide for Transplant-Ineligible Multiple Myeloma Patients: A Pooled Analysis of Two Randomized Trials

Haematologica
Hematology
2019English

Progress in the Front-Line Treatment of Multiple Myeloma

European Oncology and Haematology
OncologyHematology
2010English

Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates

Cancer Journal
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy